Want to see XWEL full AI Analyst Report?
XWELL (XWEL) AI Stock Analysis
XWELL
(NASDAQ:XWEL)
Primarily impacted by poor financial performance with revenue decline and negative equity, along with bearish technical signals. Valuation remains unattractive due to negative earnings, while corporate events show mixed outcomes from approved sale versus delisting risks.
XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.47M
- Dividend Yield
- ―
- Average Volume (3M)
- 41.74K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- -0.21
- Revenue Growth
- -7.58%
- EPS Growth
- -30.33%
- Country
- US
- Employees
- 175
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Personal Products & Services
XWELL Business Overview & Revenue Model
Company Description
XWELL Inc. functions as a health and wellness services provider, primarily operating within airports. The company delivers its diverse offerings through various brands, including XpresSpa, XpresTest, Treat, and HyperPointe. Its core services feature...
How the Company Makes Money
XWELL makes money primarily by delivering healthcare services under contract and charging service fees for clinical programs it staffs and operates. Key revenue streams include (1) fees from providing onsite/mobile health services (e.g., testing, scr...
XWELL Earnings Call Summary
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.
XWELL Financial Statement Overview
Summary
Revenue declined sharply to $28.3M with negative equity at -$1.85M and ongoing negative cash flows, indicating high risk and weak stability.
Income Statement
25NegativeBalance Sheet
15Very NegativeCash Flow
35Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.28M | 29.21M | 33.90M | 30.11M | 55.94M | 73.73M |
| Gross Profit | 8.68M | 6.64M | 8.92M | 3.68M | 12.05M | 32.34M |
| EBITDA | -21.37M | -14.16M | -9.83M | -15.75M | -17.28M | 9.86M |
| Net Income | -23.42M | -16.99M | -16.85M | -27.74M | -32.84M | 3.35M |
Balance Sheet | ||||||
| Total Assets | 20.53M | 11.22M | 25.35M | 38.99M | 70.43M | 127.27M |
| Cash, Cash Equivalents and Short-Term Investments | 11.78M | 2.62M | 11.80M | 23.05M | 42.19M | 105.51M |
| Total Debt | 7.29M | 12.49M | 10.77M | 11.09M | 14.11M | 13.82M |
| Total Liabilities | 12.27M | 23.80M | 17.61M | 18.02M | 22.48M | 27.33M |
| Stockholders Equity | -1.85M | -22.04M | -788.00K | 13.00M | 39.93M | 92.73M |
Cash Flow | ||||||
| Free Cash Flow | -13.48M | -11.68M | -12.80M | -18.45M | -31.02M | 6.97M |
| Operating Cash Flow | -11.27M | -8.71M | -11.01M | -16.07M | -24.19M | 14.56M |
| Investing Cash Flow | 689.00K | 4.33M | 5.89M | 5.65M | -34.84M | -5.16M |
| Financing Cash Flow | 17.48M | 1.94M | 1.36M | 8,000 | -27.38M | 6.35M |
XWELL Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.86, and below the 200-day MA of 1.01, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 38.54 is Neutral, neither overbought nor oversold. The STOCH value of 51.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 61 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksXWELL Peers Comparison
Overall Rating
RGS58Neutral
MED47Neutral
MRM44Neutral
EJH40.25Neutral- XWEL40Underperform
TRNR40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| RGS | 58Neutral | $74.17M | 10.75 | 3.66% | ― | 6.83% | -94.25% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MED | 47Neutral | $135.87M | -3.29 | -21.13% | ― | -30.28% | -16409.29% |
| MRM | 44Neutral | $2.61M | -0.67 | -68.38% | ― | ― | ― |
| EJH | 40Neutral | $4.19M | -0.57 | 1.38% | ― | -1.57% | ― |
| XWEL | 40Underperform | $6.88M | -0.13 | 317.52% | ― | -7.58% | -30.33% |
| TRNR | 40Underperform | $2.49M | -0.02 | -375.72% | ― | 197.50% | 99.51% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XWEL | Xwell, Inc. | 0.69 | -0.20 | -22.47% | |
| MED | Medifast | 12.15 | 0.27 | 2.27% | |
| RGS | Regis Corporation | 29.67 | 0.17 | 0.56% | |
| MRM | Medirom Healthcare Technologies, Inc. | 0.33 | -1.59 | -82.81% | |
| EJH | E-Home Household Service Holdings Ltd. | 1.31 | -23.19 | -94.65% | |
| TRNR | Interactive Strength Inc | 1.54 | -179.76 | -99.15% |
XWELL Corporate Events
XWELL Shareholders Approve Strategic Sale and Equity Expansion
PositiveOn October 28, 2026, XWELL stockholders convened a special meeting, with 5,708,101 shares represented, constituting a 53.74% quorum of the company’s voting power. Shareholders approved the Purchase Agreement among XWELL, XpresSpa, the divestitu...
XWELL Receives Nasdaq Notice for Minimum Bid Noncompliance
NegativeOn October 7, 2026, XWELL, Inc. disclosed that it had received a notice from Nasdaq stating the company was not in compliance with the exchange’s $1.00 minimum bid price requirement, after its shares traded below that threshold for 30 consecuti...
XWELL Completes XpresTest Stock Repurchase Before Sale
PositiveOn October 8, 2026, XpresTest, Inc., a subsidiary of XWELL, Inc., repurchased 279.5 shares of its common stock previously granted as restricted stock awards for approximately $2.7 million at $9,634.09 per share. The buyback covered awards held by sen...
XWELL CEO Steps Off Board, New Director Appointed
PositiveOn August 3, 2026, XWELL, Inc. announced that President and Chief Executive Officer Ezra T. Ernst resigned from the company’s Board of Directors and its committees, while retaining his executive roles. The company said the board resignation was...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 30, 2026